Methotrexate Versus Prednisone as First-Line Treatment for Pulmonary Sarcoidosis: The PREDMETH Trial
作者
Vivienne Kahlmann,Marcel Veltkamp,Catharina C. Moor,Montse Janssen Bonás,Rémy L.M. Mostard,H.N.A.J. van Rijswijk,Jan van der Maten,Emiel R. Marges,L. Moonen,Maria J. Overbeek,B. Koopman,Marco J.J.H. Grootenboers,Esther J. Nossent,Michiel Wagenaar,H. Kramer,Pascal L. M. L. Wielders,Peter Iwan Bonta,Stefan Walen,Brigitte A.H.A. Bogaarts,René Kerstens
Abstract Rationale Prednisone is first-line treatment for pulmonary sarcoidosis; however, side effects can significantly diminish quality of life. Methotrexate appears to have fewer side effects but has not been studied as first-line treatment. In the PREDMETH trial we investigated the efficacy of methotrexate compared to prednisone. We recently reported, (European Respiratory Society Conference), that methotrexate is as effective as prednisone as assessed by forced vital capacity (FVC). Here, we report the frequency of adverse events (AEs) and patient reported outcomes (PROs). Methods The PREDMETH trial was a randomized, non-inferiority trial conducted at 17 hospitals in the Netherlands (NCT04314193). The study was designed by clinicians, researchers, and patients. Treatment-naïve patients with pulmonary sarcoidosis received prednisone or methotrexate (randomization 1:1) according to a predefined schedule. The primary endpoint was change in FVC% predicted at 24 weeks (protocol:PMID33076885). Safety assessment included all physician reported (serious)AEs. PROs on symptoms and quality of life were collected at all visits. Results We randomized 138 patients; 70 patients to prednisone (1 exclusion due to an alternative diagnosis) and 68 to methotrexate. Most patients were male (73.7%) and mean age was 46.6 years (SD11.86). Baseline FVC% predicted was 79.8% (SD15.44) for prednisone and 74.8%(SD12.68) for methotrexate. At 24 weeks, there was no significant difference in between group change in %predicted FVC; -1.8% (90%CI -4.40; 0.76). A total of 83% of the prednisone group and 81% of the methotrexate group received medication as per protocol. The total number of AEs did not differ between both groups(table1). At 24 weeks fewer AEs were ongoing in the methotrexate group compared to prednisone (104 versus 171). Most frequently reported AEs in the prednisone group were increased weight, insomnia, increased appetite, and cushingoid appearance. In the methotrexate group, nausea, fatigue, abnormal liver function values, abdominal pain, and respiratory tract infection were more commonly reported. Conclusion The PREDMETH study shows that methotrexate is as effective as prednisone for pulmonary sarcoidosis as assessed by FVC after 24 weeks of treatment. The total number of side effects was comparable; however, in the methotrexate group fewer side effects were ongoing at 24 weeks. Side effect profiles were clearly different. This study shows for the first time that methotrexate may be a good alternative for prednisone as first-line treatment. Difference in AE profiles provide important grounds for shared therapeutic decision making of patients and doctors. The results on PROs will be available at the time of the ATS conference.